Aerocrine Publishes New Issue Prospectus

Aerocrine Publishes New Issue Prospectus

SOLNA, Sweden - 22 September 2010 - Aerocrine AB (OMX Nordic Exchange:
AERO B) today announces the publication of the prospectus for the
Company´s rights issue of approximately SEK 155.5 million and the
directed issue of new shares and convertible bonds of SEK 225 million to
Novo A/S.  The prospectus, available in Swedish language only, has been
approved by and registered with the Swedish Financial Supervisory
Authority (Finansinspektionen).

The prospectus is available on Aerocrine´s website,
www.aerocrine.com/sv/ (http://www.aerocrine.se/), and on Swedbank´s
website, www.swedbank.se/prospekt (http://www.swedbank.se/prospekt).  A
hard copy of the prospectus can be obtained from Aerocrine free of
charge, telephone: +46 8 629 07 80, and from Swedbank, telephone: +46
8 585 918 00 and e-mail:
emissioner.sthlm@swedbank.se (emissioner.sthlm@swedbank.se).

The prospectus will be distributed to all shareholders directly
registered in Sweden. Shareholders registered through a nominee should
contact their portfolio manager.

Aerocrine will shortly convene an extraordinary general meeting where it
will be proposed that Scott Beardsley, a senior partner with Novo Growth
Equity, is elected new member of Aerocrines' board. In conjunction
therewith, Lars Gatenbeck will leave the board.

For more information, contact: 

Paul de Potocki, CEO, telephone: +46 8 629 07 80

Michael Colérus, CFO, telephone: +46 8 629 07 85

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved
management and care of patients with inflammatory airway diseases. The
pioneer and leader in the technology to monitor and manage airway
inflammation, Aerocrine markets NIOX MINO® and NIOX® Flex. Both products
enable the fast and reliable measurement of airway inflammation and may
thus play a critical role in more effective diagnosis, treatment and
follow-up of patients with inflammatory airway diseases such as asthma.
Aerocrine is based in Sweden with subsidiaries in the US, Germany and
the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on
15 June 2007.

Aerocrine may be required to disclose the information provided herein
pursuant to the Securities Markets Act and/or the Financial Instruments
Trading Act. The information was submitted for publication at 08:00 am
on 22 September 2010.

This press release may not be made public, published or distributed,
directly or indirectly, in or into the United States, Canada, South
Africa, Australia, New Zeeland, Singapore, Hong Kong or Japan

IMPORTANT INFORMATION
In certain jurisdictions, publication or distribution of this press
release may be subject to legal restrictions and persons in those
jurisdictions where this press release has been published or distributed
should inform themselves about and abide by such legal restrictions.
This press release may not be made public, published or distributed,
directly or indirectly, in or into the United States, Canada, South
Africa, Australia, New Zeeland, Singapore, Hong Kong, Japan or in any
other country where such action is subject in full or in part to legal
restrictions, nor may the information in this press release be
forwarded, reproduced or disclosed in any way that is in conflict with
such restrictions. Failure to follow this instruction may involve a
breach of the United States Securities Act of 1933 ("Securities Act") or
applicable laws in other jurisdictions.
This press release does not contain or constitute an invitation or offer
to acquire, subscribe for or otherwise trade in shares, subscription
rights or other securities in Aerocrine. The invitation to the persons
concerned to subscribe for shares in Aerocrine will only be made through
the prospectus that Aerocrine publish in September 2010, which
prospectus, among other things, will contain financial statements and
information on the board of directors and auditor of Aerocrine.
Neither the subscription rights, the paid subscription shares (BTA) or
the new shares will be registered in accordance with the Securities Act
or any provincial act in Canada, and may not be transferred or offered
for sale in the United States or Canada, or to persons resident there,
or on behalf of such persons, other than in such exceptional cases where
registration in accordance with the Securities Act or any provincial act
in Canada is not required.